FeesSafety
Pluang+

AI leaders call for slowing development, shifting risks and opportunities in AI investments.

Market News
14 Sep 2026
Seeking Alpha
View Source
Neutral
AI leaders call for slowing development, shifting risks and opportunities in AI investments.

AI industry leaders are now advocating for a slowdown in the rapid development of AI models, marking a significant change in the risk landscape for AI investments. While this deceleration might not reduce AI adoption, it could pressure semiconductor companies and those heavily reliant on training AI models. Conversely, hyperscalers and software firms might benefit as the focus shifts from building new AI infrastructure to deploying and monetizing existing technologies. The future of AI growth now hinges not only on technological advances but also on regulatory, business, and societal acceptance.

The story on AI industry leaders calling for a slowdown in AI development provides context for technology sector investors. For readers following the technology sector, here is Pluang's market snapshot as of Sep 14, 2026 19:44 WIB: Out of 150 priced US technology stocks, 67 rose and 77 fell. Notable movers include KLAC (KLA Corp.) down 7.81% at USD 166.53, WULF (TeraWulf Inc) down 7.65% at USD 15.46, and STX (Seagate Technology Holdings PLC) down 7.43% at USD 768.49.

More News

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
1 hour ago
Darolutamide with ADT and radiation cuts metastasis or death risk by 58% in high-risk prostate cancer patients.

Darolutamide with ADT and radiation cuts metastasis or death risk by 58% in high-risk prostate cancer patients.

Interim results from the Phase 3 DASL-HiCaP trial show that adding darolutamide to standard androgen deprivation therapy (ADT) and radiation therapy reduces the risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence...

Company Fundamentals
Bullish
3 hours ago
Anthropic's revenue jumps to $16.3B in H1 2026, up from $1.1B last year

Anthropic's revenue jumps to $16.3B in H1 2026, up from $1.1B last year

Anthropic reported a massive increase in revenue, reaching $16.3 billion in the first half of 2026 compared to just $1.1 billion in the same period last year. This surge highlights rapid growth and strong demand for its products or services. The dram...

Market News
Bullish
4 hours ago
NEAR Protocol leads crypto losses with an 8.93% drop amid broader market declines

NEAR Protocol leads crypto losses with an 8.93% drop amid broader market declines

NEAR Protocol (NEAR) experienced the largest 24-hour decline among major cryptocurrencies, falling 8.93% to $4.47. Other notable drops included Bitcoin down 1.28% to $80,495, Ether down 1.38% to $2,360.57, and XRP down 3.45% to $1.28. These declines ...

Market News
Bearish
4 hours ago
XRP's 2017-18 rally gains estimated between 62,000% and 119,000%, varying by measurement methods.

XRP's 2017-18 rally gains estimated between 62,000% and 119,000%, varying by measurement methods.

Estimates of XRP's price rally during 2017-18 vary widely, from about 62,000% to 119,000%, depending on different starting prices and measurement periods. Vandell Aljarrah of Black Swan Capitalist highlighted a 630-fold rise when XRP moved above a tr...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App